Proteomic study on the mechanism and potential targets for treatment of Abnormal Savda syndrome type breast cancer with the corresponding prescription

Status

Recruiting

Phases

Phase 3

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OIC-16008170

Enrollment

Unknown

Registered

2016-03-28

Start date

2015-07-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

After western medicine treatment group:Uighur medicine prescription

Eligibility

Sex/Gender

Female

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. pathological confirmed as breast cancer; 2. without distant organ metastasis; 3. aged between 20-70 years old; 4. signed informed consent to enter the study.

Exclusion criteria

Exclusion criteria: 1. people with other metabolic diseases, such as diabetes, kidney disease, blood system diseases, etc.; 2. distant metastasis has occurred at the time of diagnosis.

Design outcomes

Primary

Measure	Time frame
Abnormal Savda;Plasma protein;	—

Countries

China

Contacts

Public ContactABUDULA ABULIZI

abulizi_de@126.com+86 13999959205

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026